Body Composition Changes, Mechanism, Obesity Rekated Cancer, Survival
Conditions
Brief summary
Over the past 20 years, China's obesity rates have surged, increasing cancer burden. Obesity links to 13 cancers via metabolic effects of visceral fat and insulin resistance, while sarcopenic obesity (BMI-independent) may worsen outcomes. Traditional BMI lacks precision; advanced methods (e.g., BIA/CT) are needed. Existing studies show inconsistent results, possibly due to heterogeneity. This multicenter prospective cohort study uses imaging to assess body composition changes (fat/muscle) in obesity-related tumors and their impact on survival, recurrence, and quality of life, and explore the underlying mechanism.
Interventions
None listed
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Age ≥18 years, regardless of gender. 2. Histologically or cytologically confirmed obesity-associated malignant tumors (e.g., breast cancer, colorectal cancer, gastric cancer, lung cancer, or thyroid cancer) with planned treatment after diagnosis (any treatment modality permitted). 3. No prior chemotherapy, radiotherapy, biologic therapy, immunotherapy, or other antitumor treatments for malignancy.
Exclusion criteria
1. Patients with concurrent non-obesity-related malignancies. 2. History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin). 3. Patients with concurrent multiorgan dysfunction syndrome, autoimmune diseases, infectious diseases, neurological disorders, or psychiatric disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From date of diagnosis until the date of death from any cause, assessed up to 10 years | The time from the start of follow-up to death (for any reason). |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival after diagnosis | From date of diagnosis until the date of first documented progression , assessed up to 10 years |
| Time of recurrence and/or distant metastasis after diagnosis | From date of diagnosis until the date of first documented recurrence and/or distant metastasis, whichever came first, assessed up to 10 years |
Countries
China
Outcome results
None listed